RA0339

antibody from Oursmab

Targeting: IL13RA1 CD213a1, IL-13Ra, NR4

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0339

Provider

Oursmab

Product name

Eblasakimab (Biosimilar Reference Antibody) (IL13RA1)

Antibody type

Monoclonal

Description

Eblasakimab is an investigational, first-in-class, fully human monoclonal antibody being developed for the treatment of moderate-to-severe atopic dermatitis (AD). It uniquely targets the IL-13 receptor alpha 1 subunit (IL-13R¦Á1), a shared component of the Type II IL-4/IL-13 receptor complex. By blocking this receptor, eblasakimab inhibits signaling from both IL-4 and IL-13, two central cytokines driving type 2 inflammation in AD. Early clinical studies have demonstrated its ability to significantly reduce key inflammatory biomarkers (e.g., TARC, IgE) and improve skin lesions, with extended dosing intervals (e.g., monthly) suggesting a durable treatment effect. This positions eblasakimab as a promising new therapeutic option alongside existing biologics like dupilumab.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.